Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS-275291

Known as: D2163, N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide, REBIMASTAT 
A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
BACKGROUND Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors… Expand
Is this relevant?
2006
2006
Background: BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the… Expand
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic… Expand
Is this relevant?
2004
2004
Purpose: This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
2004
2004
Purpose: BMS-275291 is a novel broad-spectrum inhibitor of matrix metalloproteinase (MMPs) rationally designed to spare a class… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2004
2004
BACKGROUND This randomized, double-blind, placebo-controlled study was designed to assess whether the addition of the matrix… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE The purpose of this study was to evaluate the feasibility of incorporating a novel wound angiogenesis assay into a Phase… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
Review
2003
Review
2003
  • Joyce E. Rundhaug
  • Clinical cancer research : an official journal of…
  • 2003
  • Corpus ID: 30964561
The MMPs2 are a family of zinc-containing endopeptidases that degrade various components of the ECM. A number of MMPs have been… Expand
Is this relevant?
Review
2002
Review
2002
Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BMS-275291 is an p.o. bioavailable, sulfhydryl-based matrix metalloproteinase (MMP) inhibitor currently in clinical development… Expand
  • figure 1
  • table 1
  • table 3
  • figure 2
  • figure 3
Is this relevant?